Booster dose vaccination for preventing hepatitis B
There is no scientific evidence, based on randomised clinical trials, to support or reject the need for booster doses of hepatitis B vaccine in healthy individuals with normal immune status.
Antibodies against hepatitis B surface antigen wane over time after vaccination for hepatitis B; hence, the duration of protection provided by the vaccine is still unknown but may be evaluated indirectly by measuring the anamnestic immune response to booster doses of vaccine. This review aimed to assess the benefits and harms of booster dose hepatitis B vaccination for preventing hepatitis B infection. However, there is no scientific evidence based on randomised clinical trials to support or refute the need for a booster dose of hepatitis B vaccine in healthy individuals, with normal immune status, who had fully responded to a complete course of the vaccine.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.